EU Joint Action on AMR & Health-Care Associated Infections (EU-JAMRAI): Passing the DRIVE-AB torch?

Dear All:

Recently announced is a new EU Joint Action on Antimicrobial Resistance (AMR) & Health-Care Associated Infections (HCAI). Its acronym is EU-JAMRAI and the website is

Joint actions are a common tool for coordinating implementation activities across Europe. EU-JAMRAI actually started in September 2017 and will run for three years but it is really launching itself now into the public eye with a website and newsletter. EU-JAMRAI has nine work packages (WPs, the full list is found below my signature).

Why does this matter? The bulk of EU-JAMRAI’s activity will focus on ensuring that solid national action plans exist in EU member states. But of great interest to the R&D community, it appears that WP9 (led by France and Norway) will be looking at pull incentives for Europe. To my eye, this is a very exciting development: With DRIVE-AB having come to an end with release of its final report, there is definitely a need for the torch to pass to a new group that can carry this work forward.

So, check out their website and subscribe to their newsletter! The link to subscribe to the newsletter is in the middle of the JAMRAI homepage (look just above the picture of the pigs) and unfortunately is structured so that I can’t put a copy of the signup link here.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future:

The Work Packages of EU-JAMRAI

  • Four WPs focus on project coordination, dissemination/communication of results, and evaluation of progress (WPs 1, 2, 3, and 8).
  • Two of the WPs (4 & 5) focus on implementation of One Health national strategies and national action plans.
  • WP6 seeks to create and implement policies to prevent HCAI
  • WP7 will create a database of current guidelines for antibiotic stewardship in animals & man
  • WP9 work seeks to ensure that national processes for R&D are coordinated with the One Health Approach. This WP will also explore mechanisms to increase innovation, including exploration of Pull incentives.

Upcoming meetings of interest to the AMR community:


Fireside Chat with BARDA’s Branch Chief for Antimicrobials

Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and

Japan Pulls for Pandemic Preparedness: Nikkei FT Conference

Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”

Pulling for Pandemic Preparedness

Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps

PACE: A new £30m fund for AMR innovation

Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced

Scroll to Top